| Literature DB >> 12706704 |
Geoffrey J Gorse1, Theresa Z O'Connor, Stephen L Young, Paul M Mendelman, Suzanne F Bradley, Kristin L Nichol, James H Strickland, Daniel M Paulson, Kathryn L Rice, Runi A Foster, Ashok M Fulambarker, John W Shigeoka, Ware G Kuschner, Richard P Goodman, Kathleen M Neuzil, Janet Wittes, Kathy D Boardman, Peter N Peduzzi.
Abstract
We assessed whether trivalent live, cold-adapted influenza virus (CAIV-T) vaccine provides added protection when co-administered with trivalent inactivated influenza virus vaccine (TVV) in patients with chronic obstructive pulmonary disease (COPD). Subjects (N=2215) were randomly assigned to receive either TVV intramuscularly (IM) and CAIV-T intranasally (TC), or TVV and placebo (TP). The vaccines were well-tolerated. Efficacy of TC compared to TP was not statistically significant and was 0.16 for any influenza virus strain (95% confidence limit (CL): -0.22, 0.43), 0.26 for A (H3N2) virus (95% CL: -0.17, 0.53), and -0.05 for type B virus (95% CL: -1.13, 0.48). However, there was a possible advantage for TC over TP in reducing respiratory consequences of an influenza season measured by pulmonary function and symptoms at end of study.Entities:
Mesh：
Substances：
Year: 2003 PMID： 12706704 DOI： 10.1016/s0264-410x(02)00748-x
Source DB: PubMed Journal: Vaccine ISSN： 0264-410X Impact factor: 3.641